Clinical trial · Interventional
PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma
Phase 2 Study: PET Imaging Characteristics of C11-Acetate in Patients With Prostate Carcinoma, Detection of Recurrent Disease With PSA Relapse
NCT01304485CI-TRIAL-00037491completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Positron emission tomography (PET) imaging evaluation in men with recurrent prostate cancer to select patients who may benefit from directed therapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sodium Acetate C11 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Sodium Acetate C11 PET Imaging
- interventionNames
- Drug: Sodium Acetate C11
Primary outcomes (1)
- measure
- SUV (Standardized Uptake Value)
- timeFrame
- Day1 - Assessed at time of PET imaging - i.e. at the time of primary investigation/PET agent administration
- description
- Imaging studies will be evaluated both qualitatively and quantitatively using SUV (standardized uptake values): a measure of metabolism based on injected dose, patient weight and region of interest.
Secondary outcomes (1)
- measure
- PSA (prostate specific antigen)
- timeFrame
- Every 3 - 6 months for 24 months after PET imaging
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * recurrent prostate cancer (detectable PSA following radical prostatectomy or rising PSA in patients with radiation therapy as the primary treatment) Exclusion Criteria: * \< 18 years old * claustrophobic patients
References
Publications (0)
Data not yet available
No reference posted for this study.